The national screening program for permanent neonatal hearing loss, launched in December 2014, aims to identify affected children early on to enable appropriate care. Our objective was to evaluate the implementation of this program on a national scale. The screening program consists of two phases. The first phase consists of a hearing screening performed in the maternity ward on all newborns using an initial test (T1) and a retest (T2). Depending on the region, a delayed test (T3) may be performed after discharge from the maternity ward for children in whom it was not possible to conclude that hearing was normal. The second phase of the program is, if necessary, the hearing loss diagnosis phase, which takes place in healthcare facilities, private practices, or specialized institutions. Santé publique France (SpF) was tasked by decree (Decree of November 3, 2014 (1)) with evaluating the hearing screening program on a national scale. The objective was initially limited to evaluating the implementation of screening for the most severe cases (moderate to profound) of permanent bilateral neonatal hearing loss (SPBN), due to their impact on child development. We defined the evaluation indicators after consulting with stakeholders. A computer application was developed to collect all aggregated data on screening and diagnosis for children born alive in 2015 and 2016 in each of France’s 27 regions. This made it possible to estimate the coverage rate, completeness rate, efficiency rate, refusal rate, and the number of children suspected of having SPBN at the end of the screening phase, as well as to present the distribution of deaf children according to the severity of their hearing impairment. All of this information needs to be consolidated, particularly that concerning the diagnostic phase, due to a significant amount of missing or miscoded data. An estimate of the national deafness rate was made based on a limited number of regions with a low rate of missing data. In 2015, one year after the program’s implementation began, the coverage rate was already very high (88%) and even higher in 2016 (96%). By the end of 2016, only one region (Poitou-Charentes) had not yet launched the screening program systematically in all maternity wards. The completeness rate increased significantly between 2015 and 2016 (84% vs. 94%; p